Photoimmunotherapy: Targeting Cancer Cells with Light and Antibodies
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
Shimadzu has been collaborating with Dr. Hisataka Kobayashi* of the National Cancer Institute (NCI) in his efforts to develop a revolutionary cancer therapy which selectively kills targeted cancer cells while keeping surrounding healthy cells intact by using conjugate of antibody plus the photo-absorber and near-infrared light. Many Shimadzu analytical solutions are employed in this study, including triple quadrupole mass spectrometry, liquid chromatography, spectrophotometry, high-resolution scanning probe microscopy, and near-infrared fluorescence imaging. Watch the videos and read the related articles to learn more about how the instruments are being used to improve the safety and efficacy of the therapy.
Future of Cancer Photoimmunotherapy
National Cancer Institute
Killing Cancer Cells with the Help of Infrared Light - Photoimmunotherapy
Cancer Immunotherapy: Targeting Tumors with Light and Antibodies
Rakuten Medical and Shimadzu Corporation announce a joint development and commercialization agreement on a medical device to be used with the IlluminoxTM platform
- Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1088, United States
Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy
Kazuhide Sato, Kanta Ando, Shuhei Okuyama, Shiho Moriguchi, Tairo Ogura, Shinichiro Totoki, Hirofumi Hanaoka, Tadanobu Nagaya, Ryohei Kokawa, Hideo Takakura, Masayuki Nishimura, Yoshinori Hasegawa, Peter L. Choyke, Mikako Ogawa, and Hisataka Kobayashi ACS Central Science 2018 4 (11), 1559-1569 DOI: 10.1021/acscentsci.8b00565
Real-time IR700 Fluorescence Imaging During Near-infrared Photoimmunotherapy Using a Clinically- approved Camera for Indocyanine Green
Shuhei Okuyama, Daiki Fujimura, Fuyuki Inagaki, Ryuhei Okada, Yasuhiro Maruoka, Hiroaki Wakiyama, Takuya Kato, Aki Furusawa, Peter L. Choyke and Hisataka Kobayashi CANCER DIAGNOSIS & PROGNOSIS Volume 1(2); Pages: 29-34, 2021 | DOI 0.21873/cdp.10005